维普期刊资源整合服务平台（V6.5）

73篇 您的检索式：作者名="Bokkel"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer 显示文摘	ten Bokkel Huinink W Lane SR Ross GA	1997	J Clin Oncol1997，15，6：	1
2	Rapid method for determination of fat in faeces显示文摘	Van de Kramer JH Bokkel H Weijers HA	1949	J Biol Chem1949，447，：	1
3	Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin–DNA adduct formation in patients and ovarian cancer cell lines显示文摘	P.J.M. van de Vaart N. van der Vange F.A.N Zoetmulder A.R. van Goethem O. van Tellingen W.W. ten Bokkel Huinink J.H. Beijnen H. Bartelink A.C. Begg	1997	European Journal of Cancer1997，，1：	1
4	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer 显示文摘	Gore M Carmichael J	1997	J Clin Oncol1997，15，6：	1
5	Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer 显示文摘	ten Bokkel Huinink W Carmichael J	2001	J Clin Oncol2001，19，7：	1
6	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer 显示文摘	Ten Bokkel Huinink W Gore M Carmichael J	1997	J Clin Oncol1997，15，：	1
7	European Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion 显示文摘	Eisenhauer EA ten Bokkel Huinink WW Swenerton KD	1994	J Clin Oncol1994，12，：	1
8	European- Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion显示文摘	Ten Bokkel Huinink WW Swenerton KD	1994	J Clin Oncol1994，12，12：	1
9	Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)显示文摘	Van Cutsem E Cunningham D Ten Bokkel Huinink WW	1999	Eur J Cancer1999，35，1：	1
10	Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-FU显示文摘	Van Cutsem E Cunningham D Ten Bokkel Huinink WW	1999	Eur J Cancer1999，35，1：	1
11	Clinical evidence for topotecan-paclitaxel non-cross-resistence in ovarian cancer显示文摘	Gore M ten Bokkel Huinink W Carmichael J	2001	J Clin Oncol2001，19，7：	1
12	Clinical evidence for topotecan paclitaxel non-cross-resistance in ovarian cancer显示文摘	Gore M Ten Bokkel Huinink W Carmichael J	2001	J Clin Oncol2001，19，7：	1
13	Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer显示文摘	ten Bokkel Huinink W Gore M Carmichael J	1997	J Clin Oncol1997，15，6：	1
14	A phase Ⅰ/Ⅱ and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer 显示文摘	Rea DW Nortier JW Ten Bokkel Huinink WW	2005	Ann Oncol2005，16，7：	1
15	Safety and efficacy of patupilone in patients with advanced ovarian,primary fallopian,or primary peritoneal cancer:a phase Ⅰ,open-label,dose-escalation study显示文摘	Ten Bokkel HWW Sufliarsky J Smit W	2009	J Clin Oncol2009，27，19：	1
16	Clinical evidence for topotecan-paclitaxel non -cross-resistance in ovarian cancer显示文摘	Gore M Ten Bokkel Huinink W	2001	J Clin Oncol2001，19，7：	1
17	Clinical activity and benefit of irinotecan(CPT-11)in patients with colorectal cancer truly reesistant to-florouracil(5-FU)显示文摘	Cunningham D Ten Bokkel Huinin K	1999	Eur J Cancer1999，35，1：	1
18	Clinical activity and benefit of irinotecan(CPT-11) in patients with colorectal cancer truly resistant to 5-FU显示文摘	van Cutsem E Cunningham D Ten Bokkel Huinink WW	1999	Eur J Cancer1999，35，1：	1
19	Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open?label, dose-escalation study显示文摘	Ten Bokkel Huinink WW SufliarskyJ Smit WM et at	2009	J Clin Oneol2009，27，19：	1
20	Controlled multicenter study of influence of subcutaneous recombinant human erythropoietin in patients with ovarian carcinoma treated with platinum-based chemotherapy显示文摘	de Swart CA van Toom DW	1998	Med Oncol1998，15，3：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示